Faced with a shortage of abortion pills, France is in danger not because of the decisions of French justice, but because of what has been happening recently on the other side of the Atlantic.

France gets most of its abortion drugs from the part-US company Nordic Pharma, maker of MisoOne and GyMiso.

However, supplies that were already under pressure due to shortages of raw materials are now also “at risk” due to court decisions in the US.

The decisions in question do not, of course, directly affect the right of French women to have an abortion, but they do have a decisive impact on the attitudes of authorities, institutions, and industries/businesses in the US.

US states are now rushing to stockpile abortion pills in an attempt to prevent a possible cessation of production or sales of mifepristone and misoprostol. This trend, however, combined with a pre-existing shortage of raw materials, raises concerns about the threat of shortages in France, a country where about 70% of abortions are performed using pills (mifepristone and misoprostol).

The US Supreme Court is expected to rule today in a lower US court ruling that the sale/use of mifepristone should not have been approved in the US.

However, it should be recalled that this is the same Supreme Court that last year struck down women’s previously federally guaranteed right in the US to have an abortion.

According to AFP